Overview

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Darifenacin
Mandelic Acids
Oxybutynin